The Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST) has developed an indigenous occlusion device for the non-surgical closure of Atrial Septal Defect (ASD), a ...

After years of negative or equivocal clinical trials plagued by slow enrollment and polarized opinions, a number of transcatheter devices are now available and US Food and Drug Administration approved ...

Our mission has always been to improve the quality of life for patients; indeed, we have sold over 90,000 of our ASD devices outside of the U.S. Now, with the FDA's approval, we are poised to ...

The company’s StrandDx-ASD device uses novel molecular biomarkers developed using a proprietary exposome and biological response sequencing platform. The breakthrough device designation label ...

"Our study provides evidence that the BioSTAR implant achieves comparable closure rates to the ASO device in small- to moderate-ASD," said lead study author Lee Benson, M.D., FSCAI. "Minimal ...

Dr. Nielsen further commented, "This was the first time we used the NobleStitch cardiovascular suturing device in this way. We suspected that the patient, apart from the PFO, also had a small ASD ...

A Tampa doctor has used the new ASD device since November and has done the procedure for seven patients since then. St. Joseph's Children's Hospital in Tampa has started using a new device to ...

A non-surgical closure involves the use of a device (ASD occlusion device) that can be delivered to the defective site by a catheter. At present, hospitals are dependant on imported devices at a ...

Occlutech, a leading innovator of implants to treat structural heart disease today announced that it has obtained Japanese MHW approval for its dedicated Atrial Septal Defect Closure Device.

The procedure is considered a milestone for the hospital offering complex ASD device closure. Dr Ahmad commended the collaboration of the hospital’s teams. “From the anaesthesia department to ...